Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer

Show full item record



Permalink

http://hdl.handle.net/10138/305148

Citation

Kinnunen , P T T , Murtola , T J , Talala , K , Taari , K , Tammela , T L J & Auvinen , A 2019 , ' Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer ' , Cancer Causes & Control , vol. 30 , no. 8 , pp. 877-888 . https://doi.org/10.1007/s10552-019-01195-x

Title: Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer
Author: Kinnunen, P. T. T.; Murtola, T. J.; Talala, K.; Taari, K.; Tammela, T. L. J.; Auvinen, A.
Other contributor: University of Helsinki, HUS Abdominal Center




Date: 2019-08
Language: eng
Number of pages: 12
Belongs to series: Cancer Causes & Control
ISSN: 0957-5243
DOI: https://doi.org/10.1007/s10552-019-01195-x
URI: http://hdl.handle.net/10138/305148
Abstract: PurposeAnticoagulants may reduce mortality of cancer patients, though the evidence remains controversial. We studied the association between different anticoagulants and cancer death.MethodsAll anticoagulant use during 1995-2015 was analyzed among 75,336 men in the Finnish Randomized Study of Screening for Prostate Cancer. Men with prevalent cancer were excluded. Multivariable Cox regression was performed to compare risk of death from any cancer and disease-specific death from 9 specific cancer types between (1) anticoagulant users overall and (2) warfarin users compared to anticoagulant non-users and (3) warfarin or (4) low-molecular-weight heparins (LMWH) compared to users of other anticoagulants. Medication use was analyzed as time-dependent variable to minimize immortal time bias. 1-, 2- and 3-year lag-time analyses were performed.ResultsDuring a median follow-up of 17.2years, a total of 27,233 men died of whom 8033 with cancer as the primary cause of death. In total, 32,628 men (43%) used anticoagulants. Any anticoagulant use was associated with an increased risk of cancer death (HR=2.50, 95% CI 2.37-2.64) compared to non-users. Risk was similar independent of the amount, duration, or intensity of use. The risk increase was observed both among warfarin and LMWH users, although not as strong in warfarin users. Additionally, cancer-specific risks of death were similar to overall cancer mortality in all anticoagulant categories.ConclusionOur study does not support reduced cancer mortality among anticoagulant users. Future studies on drug use and cancer mortality should be adjusted for anticoagulants as they are associated with significantly higher risk of cancer death.
Subject: Cancer mortality
Anticoagulant
Warfarin
Low-molecular weight heparins
Cohort
MOLECULAR-WEIGHT HEPARIN
POPULATION-BASED COHORT
IN-VITRO
VENOUS THROMBOEMBOLISM
METAANALYSIS
SURVIVAL
WARFARIN
METASTASIS
IMPACT
INHIBITION
3122 Cancers
3142 Public health care science, environmental and occupational health
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Kinnunen2019_Ar ... ulantsAndCancerMortali.pdf 584.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record